Companies
- Companies
- Company details
MediGene AG
Out-licensing
EndoTAG™-1 for the Treatment of Pancreatic and Hormone-resistant Breast Cancer: Starving out Cancer Cells More
Phase II Clinical Development of G207 for the Treatment of Malignant Glioma: Oncolytic Herpes Simplex Viruses More
Phase II Clinical Development of NV1020 for the Treatment of Colorectal Liver Metastases: Oncolytic Herpes Simplex Viruses More
Phase II Clinical Development of RhuDex®: Orally Available Therapy for Rheumatoid Arthritis More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 79 pages - $500
Feb 2011 - 32 pages - $125
May 2011 - 40 pages - $125
Nov 2010 - 136 pages - $600
Jul 2010 - 91 pages - $750
Aug 2010 - 42 pages - $250
Sep 2011 - 40 pages - $250
Nov 2010 - 107 pages - $600
Apr 2011 - 45 pages - $1,000
Dec 2010 - 58 pages - $1,000
Contact details
Christine Lemke
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us